bioAffinity Technologies (BIAF) stock price is $3.66, up 4.27% on the day, as of Oct 20, 2026. It has a market cap of $1.28Mn, and is classified in the Diagnostic Labs industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap1.28 Mn
P/E-0.08
P/S0.22
Div. Yield0.00
Total Debt (Qtr)59,026.00
Revenue Growth (1y) (Qtr)18.99
Add ratio to table…
About
bioAffinity Technologies develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other lung diseases using flow cytometry and automated analysis informed by machine learning. The company's primary commercial product is CyPath® Lung, which identifies and analyzes cell populations in sputum to indicate malignancy in the lung. CyPath® Lung is performed by the company's wholly owned subsidiary PPLS, a CAP-accredited and CLIA-certified clinical…
bioAffinity Technologies develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other lung diseases using flow cytometry and automated analysis informed by machine learning. The company's primary commercial product is CyPath® Lung, which identifies and analyzes cell populations in sputum to indicate malignancy in the lung. CyPath® Lung is performed by the company's wholly owned subsidiary PPLS, a CAP-accredited and CLIA-certified clinical anatomic and pathology laboratory that has operated for more than 18 years.
The company generates revenue primarily through the sale of CyPath® Lung tests to physicians who order the test to assist in assessing patients at high risk for lung cancer. Revenue is also derived from ongoing development of companion diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD) using the same flow cytometry and AI platform. Additional revenue comes from research collaborations, including those with Brooke Army Medical Center, focused on expanding the utility of bronchoscopy-collected samples for earlier lung cancer detection.
The company operates through the following segments:
CyPath® Lung: This segment focuses on the commercialization and delivery of the company's first diagnostic test for early-stage lung cancer detection. CyPath® Lung uses flow cytometry and artificial intelligence to analyze sputum samples for cancer and cancer-related cells. The test provides a physician’s report within three days of sample arrival, stratifying patients into risk categories based on a numerical probability score.
Companion Diagnostics for Asthma and COPD: This segment involves the development of diagnostic tools to quantify lung inflammation and identify patients likely to benefit from specific biologic therapies. Research in this area aims to match patients with effective treatments and monitor disease progression using sputum analysis. The segment leverages the company's flow cytometry platform with AI analysis to detect therapeutic targets such as receptors for dupilumab and benralizumab.
OncoSelect® Therapeutics: This segment conducts research on novel cancer therapeutic approaches that selectively target cancer cells. Work includes the development of topical treatments for squamous cell skin cancer based on discoveries involving the synthetic porphyrin TCPP. The company intends to seek strategic partners to advance these findings toward broad-spectrum cancer treatments. Research is conducted in laboratories at PPLS and through collaborations with academic institutions.
bioAffinity Technologies operates in the competitive lung cancer diagnostics market, where it positions itself as a provider of noninvasive, cost-effective tests with high sensitivity and specificity. The company's CyPath® Lung test demonstrates 92% sensitivity and 87% specificity for nodules under 20 mm, outperforming several competitors in balance and accuracy. Competitors include LungLB by LungLife AI, Nodify XL2 and Nodify CDT by Biodesix, and the Percepta nasal swab test by Veracyte, all of which show lower performance in key metrics or limitations in usability across patient populations.
The company serves physicians who order diagnostic tests for patients at high risk of lung cancer, particularly those with indeterminate pulmonary nodules detected by CT imaging. Specific customers include Brooke Army Medical Center, Walter Reed Medical Center, and the South Texas Audie L. Murphy Memorial Veterans Medical Center, which participate in clinical trials and research collaborations. The company also works with healthcare providers in academic, military, and VA medical centers to advance adoption of its diagnostic technology.
Sector:HealthcareSector rationaleThe company's primary revenue is generated from the sale of CyPath® Lung, a noninvasive diagnostic laboratory test for lung cancer, and the development of companion diagnostics for asthma and COPD. These activities, along with its operation of a CLIA-certified clinical laboratory and research into cancer therapeutics, fall squarely within the Healthcare sector's diagnostic and pharmaceutical industries.Industries:Diagnostic LabsDiagnostic LabsPrimaryThe company generates its primary revenue through the sale of CyPath® Lung tests, which are performed by its wholly owned subsidiary PPLS, a CLIA-certified clinical laboratory. It provides diagnostic and lab-testing services to physicians to detect early-stage lung cancer.BiotechnologyBiotechnologySecondaryThe company's OncoSelect® Therapeutics segment conducts research on novel cancer therapeutic approaches, including the development of topical treatments for squamous cell skin cancer.Classified using BQ-MICSCIK: 0001712762
Bull & bear
Investment Thesis
▲ Bull case
bioAffinity Technologies Inc. is positioned at the forefront of a structural shift in lung cancer diagnostics through its CyPath® Lung test, which leverages advanced flow cytometry and AI to detect malignancy in sputum samples with 92% sensitivity, 87% specificity, and 88% accuracy for nodules under 20mm. The company’s recent appointments of leading pulmonologists from MD Anderson, NYU Langone, and the University of Wisconsin to its Medical and Scientific Advisory Board signal deepening clinical validation and strategic alignment with top-tier oncology centers. These experts bring real-world interventional pulmonology and thoracic oncology experience that will accelerate CyPath® Lung’s integration into standard diagnostic pathways, particularly as the company pursues its 2,000-patient longitudinal study across VA medical centers and military hospitals. This trial is not merely a data-gathering exercise but a deliberate effort to generate real-world evidence for inclusion in lung cancer screening guidelines—a catalyst that could unlock broad reimbursement and adoption, especially given the rising volume of indeterminate pulmonary nodules detected via low-dose CT screening. The company’s 2025 financial results show CyPath® Lung revenue grew 87% year-over-year with test volume up 99%, confirming accelerating clinical utilization despite a decline in consolidated revenue from streamlining unprofitable legacy services at Precision Pathology Laboratory Services. This deliberate pivot toward high-value diagnostics has strengthened the balance sheet, with cash rising to $6.4 million from $1.1 million in 2024, providing a runway to fund the longitudinal trial and commercial expansion without immediate dilution risk. The upcoming physician roundtable webinar and Cleveland Clinic symposium appearance further demonstrate proactive thought leadership, positioning bioAffinity as a trusted partner in nodule management rather than just a test vendor. These unadvertised catalysts—clinical validation from elite advisors, real-world evidence generation via federal-site trials, and strategic commercial focus—suggest the market is underestimating the inflection point where CyPath® Lung transitions from a promising LDT to a reimbursable standard-of-care tool, potentially driving exponential growth in test volume and margin expansion as scale is achieved.
bioAffinity Technologies Inc. is positioned at the forefront of a structural shift in lung cancer diagnostics through its CyPath® Lung test, which leverages advanced flow cytometry and AI to detect malignancy in sputum samples with 92% sensitivity, 87% specificity, and 88% accuracy for nodules under 20mm. The company’s recent appointments of leading pulmonologists from MD Anderson, NYU Langone, and the University of Wisconsin to its Medical and Scientific Advisory Board signal deepening clinical validation and strategic alignment with top-tier oncology centers. These experts bring real-world interventional pulmonology and thoracic oncology experience that will accelerate CyPath® Lung’s integration into standard diagnostic pathways, particularly as the company pursues its 2,000-patient longitudinal study across VA medical centers and military hospitals. This trial is not merely a data-gathering exercise but a deliberate effort to generate real-world evidence for inclusion in lung cancer screening guidelines—a catalyst that could unlock broad reimbursement and adoption, especially given the rising volume of indeterminate pulmonary nodules detected via low-dose CT screening. The company’s 2025 financial results show CyPath® Lung revenue grew 87% year-over-year with test volume up 99%, confirming accelerating clinical utilization despite a decline in consolidated revenue from streamlining unprofitable legacy services at Precision Pathology Laboratory Services. This deliberate pivot toward high-value diagnostics has strengthened the balance sheet, with cash rising to $6.4 million from $1.1 million in 2024, providing a runway to fund the longitudinal trial and commercial expansion without immediate dilution risk. The upcoming physician roundtable webinar and Cleveland Clinic symposium appearance further demonstrate proactive thought leadership, positioning bioAffinity as a trusted partner in nodule management rather than just a test vendor. These unadvertised catalysts—clinical validation from elite advisors, real-world evidence generation via federal-site trials, and strategic commercial focus—suggest the market is underestimating the inflection point where CyPath® Lung transitions from a promising LDT to a reimbursable standard-of-care tool, potentially driving exponential growth in test volume and margin expansion as scale is achieved.
bioAffinity Technologies Inc. faces significant, underappreciated risks that threaten its path to profitability despite promising clinical data for CyPath® Lung, most notably its continued reliance on a single product in a highly competitive and rapidly evolving diagnostic landscape where reimbursement uncertainty and regulatory scrutiny could derail commercialization. Although the company reported an 87% year-over-year increase in CyPath® Lung revenue in 2025, this growth came alongside a 34% decline in total revenue ($6.16M vs $9.36M in 2024) due to the deliberate shedding of unprofitable legacy services at its PPLS subsidiary, revealing that core diagnostic growth is not yet sufficient to offset structural cost base reductions. The company remains deeply unprofitable, with a net loss widening to $14.9M in 2025 from $9.0M in 2024, driven by soaring SG&A expenses ($9.9M) that increased despite cost-cutting efforts, indicating inefficient commercialization or excessive investment in sales infrastructure ahead of demonstrable market demand. Furthermore, the longitudinal clinical study, while strategically important, introduces execution risks including patient enrollment delays, site performance variability, and the possibility that real-world data fails to replicate the 92% sensitivity seen in earlier controlled trials—especially given the study’s broader nodule size range (6mm to 30mm) and inclusion of comorbid populations like COPD and emphysema patients, where inflammatory conditions could trigger false positives and undermine specificity. The company’s financials also reveal a mounting accumulated deficit of $68.6M and significant dilution pressure, with common shares outstanding increasing over 7.6-fold from 519,158 in 2024 to 4,498,675 in 2025 post-reverse split, reflecting aggressive capital raising to sustain operations. Crucially, CyPath® Lung remains an LDT subject to potential FDA enforcement actions under evolving LDT oversight, and the company offers no clear timeline for achieving profitability or securing broad third-party reimbursement—key barriers that could leave it stranded as a scientifically valid but commercially unviable niche product, especially if larger diagnostics firms enter the space with FDA-cleared alternatives backed by stronger reimbursement networks. These unspoken hurdles—persistent losses, dilution, regulatory overhang, and unproven commercial scalability—suggest the market may be ignoring the near-term fragility of bioAffinity’s business model despite its clinical promise.
bioAffinity Technologies Inc. faces significant, underappreciated risks that threaten its path to profitability despite promising clinical data for CyPath® Lung, most notably its continued reliance on a single product in a highly competitive and rapidly evolving diagnostic landscape where reimbursement uncertainty and regulatory scrutiny could derail commercialization. Although the company reported an 87% year-over-year increase in CyPath® Lung revenue in 2025, this growth came alongside a 34% decline in total revenue ($6.16M vs $9.36M in 2024) due to the deliberate shedding of unprofitable legacy services at its PPLS subsidiary, revealing that core diagnostic growth is not yet sufficient to offset structural cost base reductions. The company remains deeply unprofitable, with a net loss widening to $14.9M in 2025 from $9.0M in 2024, driven by soaring SG&A expenses ($9.9M) that increased despite cost-cutting efforts, indicating inefficient commercialization or excessive investment in sales infrastructure ahead of demonstrable market demand. Furthermore, the longitudinal clinical study, while strategically important, introduces execution risks including patient enrollment delays, site performance variability, and the possibility that real-world data fails to replicate the 92% sensitivity seen in earlier controlled trials—especially given the study’s broader nodule size range (6mm to 30mm) and inclusion of comorbid populations like COPD and emphysema patients, where inflammatory conditions could trigger false positives and undermine specificity. The company’s financials also reveal a mounting accumulated deficit of $68.6M and significant dilution pressure, with common shares outstanding increasing over 7.6-fold from 519,158 in 2024 to 4,498,675 in 2025 post-reverse split, reflecting aggressive capital raising to sustain operations. Crucially, CyPath® Lung remains an LDT subject to potential FDA enforcement actions under evolving LDT oversight, and the company offers no clear timeline for achieving profitability or securing broad third-party reimbursement—key barriers that could leave it stranded as a scientifically valid but commercially unviable niche product, especially if larger diagnostics firms enter the space with FDA-cleared alternatives backed by stronger reimbursement networks. These unspoken hurdles—persistent losses, dilution, regulatory overhang, and unproven commercial scalability—suggest the market may be ignoring the near-term fragility of bioAffinity’s business model despite its clinical promise.